200 related articles for article (PubMed ID: 9924533)
1. Treatment of antimony-unresponsive Indian visceral leishmaniasis with ultra-short courses of amphotericin-B-lipid complex.
Sundar S; Goyal AK; More DK; Singh MK; Murray HW
Ann Trop Med Parasitol; 1998 Oct; 92(7):755-64. PubMed ID: 9924533
[TBL] [Abstract][Full Text] [Related]
2. Amphotericin B lipid complex in the management of antimony unresponsive Indian visceral leishmaniasis.
Sundar S; Goyal AK; Mandal AK; Makharia MK; Singh VP; Murray HW
J Assoc Physicians India; 1999 Feb; 47(2):186-8. PubMed ID: 10999086
[TBL] [Abstract][Full Text] [Related]
3. Short-course, cost-effective treatment with amphotericin B-fat emulsion cures visceral leishmaniasis.
Sundar S; Gupta LB; Rastogi V; Agrawal G; Murray HW
Trans R Soc Trop Med Hyg; 2000; 94(2):200-4. PubMed ID: 10897369
[TBL] [Abstract][Full Text] [Related]
4. Cure of antimony-unresponsive Indian visceral leishmaniasis with amphotericin B lipid complex.
Sundar S; Murray HW
J Infect Dis; 1996 Mar; 173(3):762-5. PubMed ID: 8627049
[TBL] [Abstract][Full Text] [Related]
5. Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study.
Laguna F; Videla S; Jiménez-Mejías ME; Sirera G; Torre-Cisneros J; Ribera E; Prados D; Clotet B; Sust M; López-Vélez R; Alvar J;
J Antimicrob Chemother; 2003 Sep; 52(3):464-8. PubMed ID: 12888588
[TBL] [Abstract][Full Text] [Related]
6. Progress in the treatment of a neglected infectious disease: visceral leishmaniasis.
Murray HW
Expert Rev Anti Infect Ther; 2004 Apr; 2(2):279-92. PubMed ID: 15482193
[TBL] [Abstract][Full Text] [Related]
7. Single-dose liposomal amphotericin B for visceral leishmaniasis in India.
Sundar S; Chakravarty J; Agarwal D; Rai M; Murray HW
N Engl J Med; 2010 Feb; 362(6):504-12. PubMed ID: 20147716
[TBL] [Abstract][Full Text] [Related]
8. Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony.
Sundar S; Agrawal NK; Sinha PR; Horwith GS; Murray HW
Ann Intern Med; 1997 Jul; 127(2):133-7. PubMed ID: 9230003
[TBL] [Abstract][Full Text] [Related]
9. Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients.
López-Vélez R; Videla S; Márquez M; Boix V; Jiménez-Mejías ME; Górgolas M; Arribas JR; Salas A; Laguna F; Sust M; Cañavate C; Alvar J;
J Antimicrob Chemother; 2004 Mar; 53(3):540-3. PubMed ID: 14739148
[TBL] [Abstract][Full Text] [Related]
10. Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis.
Sundar S; Mehta H; Chhabra A; Singh V; Chauhan V; Desjeux P; Rai M
Clin Infect Dis; 2006 Mar; 42(5):608-13. PubMed ID: 16447104
[TBL] [Abstract][Full Text] [Related]
11. Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study.
Sundar S; Jha TK; Thakur CP; Mishra M; Singh VR; Buffels R
Am J Trop Med Hyg; 2002 Feb; 66(2):143-6. PubMed ID: 12135284
[TBL] [Abstract][Full Text] [Related]
12. Amphotericin B--fat emulsion in treatment of visceral leishmaniasis--a cost effective substitute for liposomal amphotericin B.
Singh GP; Saxena RK; Priyadarshy V
J Indian Med Assoc; 2010 Jan; 108(1):27-8. PubMed ID: 20839576
[TBL] [Abstract][Full Text] [Related]
13. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
Sundar S; Sinha PK; Rai M; Verma DK; Nawin K; Alam S; Chakravarty J; Vaillant M; Verma N; Pandey K; Kumari P; Lal CS; Arora R; Sharma B; Ellis S; Strub-Wourgaft N; Balasegaram M; Olliaro P; Das P; Modabber F
Lancet; 2011 Feb; 377(9764):477-86. PubMed ID: 21255828
[TBL] [Abstract][Full Text] [Related]
14. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations.
Sundar S; Mehta H; Suresh AV; Singh SP; Rai M; Murray HW
Clin Infect Dis; 2004 Feb; 38(3):377-83. PubMed ID: 14727208
[TBL] [Abstract][Full Text] [Related]
15. Drug resistance in Indian visceral leishmaniasis.
Sundar S
Trop Med Int Health; 2001 Nov; 6(11):849-54. PubMed ID: 11703838
[TBL] [Abstract][Full Text] [Related]
16. Liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients.
Cagnoni PJ
J Antimicrob Chemother; 2002 Feb; 49 Suppl 1():81-6. PubMed ID: 11801587
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial.
Sundar S; Agrawal G; Rai M; Makharia MK; Murray HW
BMJ; 2001 Aug; 323(7310):419-22. PubMed ID: 11520836
[TBL] [Abstract][Full Text] [Related]
18. Safety of a pre-formulated amphotericin B lipid emulsion for the treatment of Indian Kala-azar.
Sundar S; Chakravarty J; Agarwal D; Shah A; Agrawal N; Rai M
Trop Med Int Health; 2008 Sep; 13(9):1208-12. PubMed ID: 18664241
[TBL] [Abstract][Full Text] [Related]
19. Amphotericin B therapy in children with visceral leishmaniasis: daily vs. alternate day, a randomized trial.
Singh UK; Prasad R; Jaiswal BP; Singh PK; Thakur CP
J Trop Pediatr; 2010 Oct; 56(5):321-4. PubMed ID: 20065047
[TBL] [Abstract][Full Text] [Related]
20. Comparison of treatment regimens of kala-azar based on culture & sensitivity of amastigotes to sodium antimony gluconate.
Thakur CP; Thakur S; Narayan S; Sinha A
Indian J Med Res; 2008 Jun; 127(6):582-8. PubMed ID: 18765878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]